JP Morgan Chase
SLXN icon

JP Morgan Chase’s Silexion Therapeutics SLXN Stock Holding History

JP Morgan Chase’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7 Buy
+1
New +$30 ﹤0.01% 8083

Other funds holding SLXN

WAM
Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $243M AUM 30.88% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

JP Morgan Chase's SLXN Position: Q3 2026 in Review

JP Morgan Chase opened a new position in Silexion Therapeutics (SLXN) in Q3 2026: 1 share worth $7. The stake represents ﹤0.01% of the portfolio and ranks #8083 among its holdings.

5 funds tracked by Wall St. Rank hold SLXN as of Q3 2026.

  • JP Morgan Chase held 1 share of Silexion Therapeutics worth $7 as of Q3 2026.
  • Silexion Therapeutics was a new JP Morgan Chase position in Q3 2026.
  • Silexion Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8083 holding.
  • 5 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.